Connect with BÜHLMANN during virtual ECCO 2022
The broadest fecal calprotectin portfolio from lab to patient,
and the exclusive offer of the complete rapid TDM for biologics
and its antibodies on Quantum Blue®
Calprotectin in IBD Diagnosis and Monitoring
Inflammatory Bowel Disease (IBD) includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), two currently incurable serious chronic diseases of the intestinal tract. IBD symptoms strongly resemble those of non-inflammatory diseases such as irritable bowel syndrome (IBS). Fecal calprotectin has proven itself as an excellent surrogate marker in IBD diagnosis and helps to reliably select patients for further invasive diagnostic procedures. Further, calprotectin in stool can also be used for disease monitoring in diagnosed patients since it correlates closely with mucosal healing. High calprotectin values are indicative for active inflammation in the gut, while moderate fecal calprotectin values can represent mild organic disease. In addition to fecal calprotectin, the monitoring of biologics trough levels (TDM) as part of the therapeutic follow-up in IBD patients is becoming standard care. Taken all this together, BÜHLMANN offers the broadest product portfolio supporting decision making in the IBD treatment management. Further, BÜHLMANN is the only company offering biologic trough level measuring as well as anti-biologic antibody testing as rapid tests.
BÜHLMANN Highlights at ECCO 2022
Quantum Blue® TDM measures originator agents as well as their biosimilars
The Quantum Blue® TDM rapid tests are capable to detect quantitative trough levels of originator agents as well as their biosimilars allowing for identification of patients with suboptimal levels as part of their TDM.
Standardization of Quantum Blue® Rapid TDM Assays with WHO International Standards
TDM of inflammatory bowel disease (IBD) patients under therapy with biologics is based on trough level determination. An international reference material allows a solid traceability and standardization of measurements and improves comparability among different assays. This standardization was presented for the Quantum Blue® TDM assays.
CALEX® Cap Stool Collection Set
The CALEX® Cap Collection Set allows for home stool collection at patients home. Using the CALEX® Cap extraction device, both fecal calprotectin and p-elastase can be measured out of the same extraction tube. The CALEX® Cap Collection Set is fully compatible with the BÜHLMANN fecal calprotectin and pancreatic elastase assays.
Product Portfolio for IBD diagnosis and therapeutic monitoring
BÜHLMANN Laboratories AG offers a broad product portfolio for diagnosis and therapeutic monitoring of Inflammatory Bowel Disease (IBD) patients. In its portfolio, Quantum Blue® Calprotectin and TDM rapid tests enable near-patient testing for inflammation, drug levels and drug antibody levels for comprehensive IBD patient care within minutes.
BÜHLMANN Calprotectin Assays and TDM Testing
BÜHLMANN is gold standard for IBD diagnosis and monitoring offering the largest product portfolio of calprotectin testing and TDM rapid tests for biologics in IBD. The product portfolio includes the FDA cleared market leader BÜHLMANN fCAL® ELISA, the FDA cleared BÜHLMANN fCAL® turbo for high throughput testing and the Quantum Blue® calprotectin rapid POC tests. BÜHLMANN Quantum Blue® TDM rapid tests offer patients biologics levels within 15 minutes. IBDoc® is the highly successful IBD home test for patients using an app that transforms smartphones into a fecal calprotectin test reading device.
The BÜHLMANN Quantum Blue® rapid test combines the ease and speed of lateral flow technology, with full quantification by means of a small reading device. The Quantum Blue® Reader provides a quantitative value within minutes and is therefore an ideal tool in a point-of-care setting. The BÜHLMANN product line offers two different fecal calprotectin test ranges suitable for IBD diagnosis and therapy follow-up of IBD patients. Besides calprotectin assays, BÜHLMANN offers the possibility for TDM for biologics in IBD on the Quantum Blue® Reader.
IBDoc® is the first in-vitro diagnostic home testing device measuring the inflammatory marker fecal calprotectin at home. The CalApp® turns your smartphone into a test cassette reader using state of the art image processing. Stool extraction is performed using the CALEX® Valve that is characterized by its simple and convenient handling of stool samples. The secure connection of CalApp® with the IBDoc® Portal allows Health Care Professionals to directly monitor patient results. The IBDoc® Portal also includes an application programming interface (api) that allows to directly transfer test results into an electronic patient record (EHR) or laboratory information system (LIMS) via a common web standard or HL7 based interface.
The CALEX® Cap Collection Set shifts the stool collection to patients home, allowing to further simplify the complete stool extraction procedure of fecal calprotectin and pancreatic elastase. It is fully compatible with the BÜHLMANN fecal calprotectin and p-elastase assays and provides the laboratory with a ready-to-use extract for safe, fast and reliable analyte measurements. The CALEX® Cap extraction device offers an efficient, convenient and hygienic home stool collection.
BÜHLMANN CALEX® Cap extraction device offers an efficient, convenient and hygienic stool extraction. Its simple design makes it an ideal extraction device characterized not only by high safety but also by offering high stability of stool samples. Furthermore, the CALEX® Cap is fully compatible with total laboratory automation (TLA) solutions increasing the speed of sample processing and reducing hands-on time.
BÜHLMANN has introduced BÜHLMANN fCAL® turbo, the immuno turbidimetric fecal calprotectin assay. The technology of immunoturbidimetry implements a further milestone in fecal calprotectin quantification. It allows very rapid and flexible random access use, as well as being the ideal solution for high throughput applications in the routine laboratory. The assay can be applied on all automated platforms in clinical chemistry and allows short turnaround time from stool sample to reportable result.
BÜHLMANN has launched its first assay for fecal calprotectin testing more than 15 years ago and is today considered as the gold standard with the BÜHLMANN fCAL® ELISA. Two protocols are available with the BÜHLMANN fCAL® ELISA to cover different calprotectin ranges for IBD diagnosis and monitoring.